CMRX - Chimerix, Inc.
| Previous Close | 4.15 |
| Open | 4.15 |
| Bid | 3.50 x 900 |
| Ask | 5.12 x 800 |
| Day's Range | 3.98 - 4.17 |
| 52 Week Range | 3.96 - 5.94 |
| Volume | 92,764 |
| Avg. Volume | 173,828 |
| Market Cap | 194.507M |
| Beta | 1.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.55 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.40 |
- Zacks•10 days ago
Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of 11.36% and 27.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•10 days ago
Chimerix: 2Q Earnings Snapshot
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 39 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- GlobeNewswire•10 days ago
Chimerix Announces Second Quarter 2018 Financial Results
DURHAM, N.C., Aug. 08, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results and provided a corporate update for the ...
- ACCESSWIRE•10 days ago
Chimerix, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30 AM Eastern Time. To ...
- GlobeNewswire•17 days ago
Chimerix to Announce Second Quarter 2018 Financial Results on August 8, 2018
DURHAM, N.C., Aug. 01, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast ...
Market Realist•25 days agoContraVir Stock Rose on Clinical Trial Progress Report
On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for Webster Financial, Chimerix, Commerce Bancshares, Teligent, Pinnacle Financial Partners, and Empire State Realty Trust — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Webster ...
- GlobeNewswire•2 months ago
Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced results from preclinical studies supporting further evaluation of CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. CMX521 showed activity in vitro against all strains of norovirus tested, suggesting broad efficacy against human noroviruses and supporting the ongoing Phase 1 study. The data will be presented in an oral and poster presentation at the 31st International Conference on Antiviral Research (ICAR) hosted by the International Society for Antiviral Research (ISAR) in Porto, Portugal.
- Benzinga•2 months ago
The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs
The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves . Nektar Therapeutics (NASDAQ: NKTR ) slumped about 42 percent, while Deciphera Pharmaceuticals ...
- American City Business Journals•2 months ago
What new FDA designation means for Durham's Chimerix
Durham-based biopharma Chimerix has banked a new designation from the U.S. Food and Drug Administration.
- Benzinga•2 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Five Below Inc (NASDAQ: FIVE ) stock was trading higher ...
- GlobeNewswire•2 months ago
Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for brincidofovir for the treatment of smallpox. Chimerix has been working with the Biomedical Advanced Research and Development Authority (BARDA) since 2011 to develop brincidofovir as a medical countermeasure for smallpox, demonstrating improved survival rates following confirmed orthopoxvirus infections in multiple animal models.
- GlobeNewswire•2 months ago
Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey, MD, MPH will deliver remarks before the House Committee on Energy and Commerce Subcommittee on Health at the hearing titled “Examining the Reauthorization of the Pandemic and All-Hazards Preparedness Act” at 10 a.m. ET on Wednesday, June 6 in Washington, D.C. The purpose of the hearing is to reauthorize certain programs under the Pandemic and All-Hazards Preparedness Act (PAHPA), which originally passed in 2006 and seeks to improve the United States’ public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental or natural. The draft reauthorization legislation would increase funding for the Biomedical Advanced Research and Development Authority (BARDA) and the Project BioShield Special Reserve Fund, a secure funding source for the purchase and stockpile of critical medical countermeasures such as vaccines, therapeutics and diagnostics.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of CMRX earnings conference call or presentation 7-May-18 12:30pm GMT
Q1 2018 Chimerix Inc Earnings Call
- Simply Wall St.•3 months ago
Want To Invest In Chimerix Inc (NASDAQ:CMRX)? Here’s How It Performed Lately
Examining how Chimerix Inc (NASDAQ:CMRX) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense check toRead More...
- Associated Press•3 months ago
Chimerix: 1Q Earnings Snapshot
The Durham, North Carolina-based company said it had a loss of 42 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
- ACCESSWIRE•3 months ago
Chimerix, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 8:30 AM Eastern Time. To listen ...
- American City Business Journals•5 months ago
Look what Triangle woman just became chairwoman of a $250M company
Amid pushing its antiviral drug forward, Durham-based Chimerix (Nasdaq:CMRX) has made a number of new additions to its board of directors and named a female board chair.
- American City Business Journals•5 months ago
Durham pharma pushing to fight a common cold virus that's deadly to some patients
For Durham-based Chimerix, fighting a virus known to cause the common cold is not a task it takes lightly.
